AvaliaÃÃo dos efeitos do inibidor de fosfodiesterase 5 sobre a ovogÃnese de camundongos

AUTOR(ES)
DATA DE PUBLICAÇÃO

2009

RESUMO

Vardenafil citrate is a potent vasodilator, with use in the treatment of patients with erectile dysfunction. Its mechanism of action is based on selective inhibition of phosphodiesterase-5 (PDE5), specific to guanosine 3â,5â-cyclic monophosphate (cGMP). The phosphodiesterases are enzymes capable of regulating the levels of cAMP (adenosine 3â,5â-cyclic monophosphate ) and cGMP by hydrolysis, its role has been indicated as a target for new therapeutic agents that act through the inhibition of their isoenzymes. The chronic treatment with Vardenafil has been used successfully in cases of pulmonary hypertension, where the progression of the disease can lead to right ventricular failure and subsequent death of the patient. Despite being used in high doses for long periods, little is known about its effects on other systems, since the cyclic nucleotides cAMP and cGMP have different effects according to the cell type, and their ovarian functions are not well described. The lack of information about the activity of Vardenafil in other cells, it is necessary to study the mechanism of action of this drug on the ovogenesis in patients undergoing therapy with oral Vardenafil, since PDE5 has been characterized in follicles and oocytes (SASSEVILLE et al, 2005). Mice were treated with the inhibitor of phosphodiesterase Vardenafil, which increases the levels of intracellular cGMP, and their ovaries used to assess the effects of this drug. This study demonstrates that treatment with the inhibitor of phosphodiesterase 5 alters the morphology of luteal cells, suggesting that induce high levels of cGMP may affect these cells

ASSUNTO(S)

quimica dos produtos naturais phosphodiesterase enzimas enzymes fosfodiesterase-5 ipde5 ipde5

Documentos Relacionados